Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report

Antibodies blocking the calcitonin gene-related peptide have revolutionized episodic and chronic migraine treatment. However, their applicability to non-cephalic pain conditions, such as osteoarthritis, is yet unknown. Osteoarthritis remains a clinical challenge, associated with high disability and limited treatment options. Like migraine, neuropeptides including calcitonin gene-related peptides are involved in its pathophysiology. We present the first case of a patient: a 73-year-old female with osteoarthritis who received monthly treatment for her chronic migraine with 140 mg subcutaneous erenumab, a monoclonal antibody against the receptor of calcitonin gene-related peptide. Though the migraine was unresponsive, the patient’s arthritic symptoms improved drastically during treatment period with erenumab; daily pain decreased from VAS 7 to 2, and walking distance doubled from 1,000 m to 2,000 m. The arthritic symptoms relapsed after discontinuation of erenumab. Erenumab could potentially have beneficial effects on symptoms of osteoarthritis. Future studies investigating these effects are warranted.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report ; volume:15 ; number:1 ; year:2023 ; pages:95-99 ; extent:5 ; Case reports in neurology ; 15, Heft 1 (2023), 95-99 (gesamt 5)

Contributors, Places and Time

• Creator: Jantzen, Frederik Thal ; Christensen, Rune Häckert ; Chaudhry, Basit Ali ; Amin, Faisal Mohammad

Further information

• DOI: 10.1159/000530138
• URN: urn:nbn:de:101:1-2024010323444726958269
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:31 AM CEST